Endocrinology Today—June 23, 2026

This week’s Endocrinology update highlights regulatory progress, advancing clinical data, rare disease innovation, updated clinical guidance, and emerging research shaping endocrine care.

In Today’s Newsletter

Dive deeper

💉 Setmelanotide Phase 2 data in Prader-Willi syndrome [1] [US • 14 Jun 2026]

https://firstwordpharma.com/story/7592374
Context: Rhythm Pharmaceuticals evaluated setmelanotide in an ongoing 52-week Phase 2 trial in Prader-Willi syndrome, with 17 patients on active therapy as of 12 Jun 2026.
Key point: Six-month data showed mean BMI reduction, fat-mass reduction with lean-mass preservation, and improvements in hyperphagia and anxiety measures.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 MAR002 Phase 1 acromegaly data [2] [US • 15 Jun 2026]

https://www.businesswire.com/news/home/20260614206691/en/Marea-Therapeutics-Presents-Phase-1-Data-Supporting-Potential-Best-in-Disease-Profile-of-MAR002-for-the-Treatment-of-Acromegaly-at-ENDO-2026
Context: Marea Therapeutics reported first-in-human Phase 1 data for MAR002, an allosteric monoclonal antibody targeting the growth hormone receptor.
Key point: MAR002 showed dose-dependent IGF-1 suppression up to 64% in healthy adult male volunteers, with a profile that may support bi-weekly to monthly dosing.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 OPK8801001 preclinical acromegaly data [3] [US • 15 Jun 2026]

https://www.opko.com/investors/news-events/press-releases/detail/547/preclinical-data-for-opko-biologics-opk8801001-in-acromegaly-presented-at-endo-2026
Context: OPKO Biologics presented preclinical ENDO 2026 data for OPK8801001, a long-acting human growth hormone receptor antagonist.
Key point: In vivo data showed sustained, dose-dependent IGF-1 suppression, and in vitro data showed growth hormone receptor antagonism about 20-fold greater than pegvisomant.
Implication: Signals pipeline investment and modality expansion.

🍽️ BioChaperone Lispro Phase 3 type 2 diabetes data [4] [China • 08 Jun 2026]

https://www.businesswire.com/news/home/20260607830413/en/ADOCIA-Announces-THDB0206-BioChaperone-Lispro-Phase-3-Data-in-Type-2-Diabetes-Presented-at-ADA-86th-Scientific-Sessions-Confirming-the-Positive-Results-Previously-Announced-in-July-2025
Context: Adocia reported full Phase 3 data from Study THDB0206L02 in more than 1,000 people with type 2 diabetes in China.
Key point: BioChaperone Lispro confirmed non-inferior HbA1c reduction versus Humalog and showed reported advantages in daily and post-meal glucose control.
Implication: May influence prescriber choice and payer reviews pending full data.

⚕️ Glucocorticoid-induced adrenal insufficiency guidance [5] [17 Jun 2026]

https://reference.medscape.com/cc2/p10/glucocorticoid-adrenal-insufficiency-guidelines-2026a1000j40#3
Context: Medscape summarized ESE and Endocrine Society guidance on glucocorticoid-induced adrenal insufficiency diagnosis and management.
Key point: The guidance highlights risk after ≥3–4 weeks of supraphysiologic glucocorticoid exposure and recommends patient education, careful tapering, morning cortisol testing, and stress-dose coverage.
Implication: May standardize clinical decision-making for tapering, recovery testing, and suspected adrenal crisis.

🧫 Thyroid cancer and reproductive hormone exposure [6] [Korea • 16 Jun 2026]

https://ascopost.com/news/june-2026/thyroid-cancer-reproductive-lifespan-hormone-therapy-potentially-linked-to-incidence/
Context: Korean researchers conducted a retrospective cohort study of 5,659,432 women aged 40 years or older using national screening and claims data.
Key point: Longer reproductive lifespan and longer hormone replacement therapy exposure were potentially associated with higher thyroid cancer incidence.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

📄 Relacorilant NDA resubmission in Cushing’s syndrome [7] [US • 18 Jun 2026]

https://www.biospace.com/press-releases/corcept-resubmits-new-drug-application-for-relacorilant-as-a-treatment-for-patients-with-cushings-syndrome
Context: Corcept Therapeutics resubmitted the relacorilant NDA to the FDA for Cushing’s syndrome after adding analyses requested by the agency.
Key point: Corcept expects a six-month review, with the application supported by GRACE, GRADIENT, long-term extension, and earlier-stage data.
Implication: Regulatory review could affect future treatment options and formulary planning.

🧫 Sernova Cell Pouch orphan drug designation [8] [US • 17 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/17/3313292/0/en/sernova-biotherapeutics-receives-fda-orphan-drug-designation-for-autologous-islet-transplantation-for-prevention-of-diabetes-due-to-total-pancreatectomy.html
Context: Sernova Biotherapeutics received FDA orphan drug designation for autologous islet transplantation to prevent diabetes after total pancreatectomy.
Key point: The approach places a patient’s own insulin-producing islet cells into Sernova’s Cell Pouch, with the goal of preserving insulin production without immune suppression.
Implication: Introduces a development pathway that may support incentives and future access planning if approved.

Why it matters

Rare endocrine disease pipelines are shifting toward mechanism-targeted approaches, including MC4R agonism, growth hormone receptor antagonism, and cell-based transplantation.
Acromegaly remains a competitive area, with both clinical and preclinical programs targeting IGF-1 control and dosing convenience.
Diabetes innovation is spanning fast-acting insulin formulations and regenerative approaches for post-pancreatectomy diabetes prevention.
Regulatory activity remains important, with Corcept’s relacorilant review and Sernova’s orphan designation creating near-term watchpoints.
Large observational datasets may refine thyroid cancer risk assessment, but interpretation depends on study design and confounding control.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Endocrinology archive on our research hub page.

FAQ

What did Rhythm report for setmelanotide in Prader-Willi syndrome?

Rhythm reported six-month Phase 2 improvements across BMI, body composition, hyperphagia, and anxiety measures in patients with Prader-Willi syndrome. The 52-week study remains ongoing. [1]

How does MAR002 differ from current acromegaly treatment approaches?

MAR002 is an allosteric monoclonal antibody targeting the growth hormone receptor. Marea said Phase 1 data showed IGF-1 suppression and pharmacokinetics that may support less frequent dosing. [2]

What stage is OPKO’s OPK8801001 in for acromegaly?

OPK8801001 is at the preclinical data stage in the supplied source. OPKO reported sustained IGF-1 suppression in vivo and stronger in vitro receptor antagonism versus pegvisomant. [3]

What did Adocia report for BioChaperone Lispro in type 2 diabetes?

Adocia reported full Phase 3 data in China, confirming non-inferior HbA1c reduction versus Humalog and reported glucose-control benefits in subgroups and post-meal measures. [4]

What is the FDA status of Corcept’s relacorilant in Cushing’s syndrome?

Corcept resubmitted the relacorilant NDA to the FDA with additional analyses requested by the agency. The company expects a six-month review. [7]

What does Sernova’s orphan drug designation cover?

The FDA designation covers autologous islet transplantation for prevention of diabetes due to total pancreatectomy. Orphan designation is not FDA approval. [8]

Entities / Keywords

Rhythm Pharmaceuticals, setmelanotide, IMCIVREE, MC4R agonist, Prader-Willi syndrome, PWS, hyperphagia, BMI z-score
Marea Therapeutics, MAR002, growth hormone receptor, GHR, acromegaly, IGF-1, monoclonal antibody
OPKO Health, OPKO Biologics, OPK8801001, long-acting hGH receptor antagonist, pegvisomant, acromegaly
Adocia, Tonghua Dongbao, THDB0206, BioChaperone Lispro, insulin lispro, Humalog, type 2 diabetes, ADA 2026
European Society of Endocrinology, Endocrine Society, glucocorticoid-induced adrenal insufficiency, HPA axis, adrenal crisis
ASCO Post, thyroid cancer, reproductive lifespan, hormone replacement therapy, Korean National Health Insurance Service
Corcept Therapeutics, relacorilant, Cushing’s syndrome, hypercortisolism, GRACE, GRADIENT, FDA NDA
Sernova Biotherapeutics, Cell Pouch, autologous islet transplantation, total pancreatectomy, type 3c diabetes, orphan drug designation